Gilead continues dealmaking streak with $3.15B Tubulis buy for ADCs

In its third ac­qui­si­tion of 2026, Gilead is spend­ing $3.15 bil­lion up­front to snag a next-gen­er­a­tion an­ti­body-drug con­ju­gate plat­form from Ger­man start­up Tubu­lis.

The Cal­i­for­nia …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.